225 related articles for article (PubMed ID: 19728885)
1. Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice.
Leszczyńska K; Namiot A; Fein DE; Wen Q; Namiot Z; Savage PB; Diamond S; Janmey PA; Bucki R
BMC Microbiol; 2009 Sep; 9():187. PubMed ID: 19728885
[TBL] [Abstract][Full Text] [Related]
2. Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13.
Bucki R; Namiot DB; Namiot Z; Savage PB; Janmey PA
J Antimicrob Chemother; 2008 Aug; 62(2):329-35. PubMed ID: 18456648
[TBL] [Abstract][Full Text] [Related]
3. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori.
Hase K; Murakami M; Iimura M; Cole SP; Horibe Y; Ohtake T; Obonyo M; Gallo RL; Eckmann L; Kagnoff MF
Gastroenterology; 2003 Dec; 125(6):1613-25. PubMed ID: 14724813
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58.
Wnorowska U; Niemirowicz K; Myint M; Diamond SL; Wróblewska M; Savage PB; Janmey PA; Bucki R
Antimicrob Agents Chemother; 2015 Jul; 59(7):3808-15. PubMed ID: 25870055
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal Activity of Ceragenin CSA-13 in Cell Culture and in an Animal Model of Peritoneal Infection.
Bucki R; Niemirowicz K; Wnorowska U; Byfield FJ; Piktel E; Wątek M; Janmey PA; Savage PB
Antimicrob Agents Chemother; 2015 Oct; 59(10):6274-82. PubMed ID: 26248361
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of
Murray BO; Dawson RA; Alsharaf LM; Anne Winter J
Microbiology (Reading); 2020 Aug; 166(8):751-758. PubMed ID: 32463354
[TBL] [Abstract][Full Text] [Related]
7. Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance.
Nuding S; Gersemann M; Hosaka Y; Konietzny S; Schaefer C; Beisner J; Schroeder BO; Ostaff MJ; Saigenji K; Ott G; Schaller M; Stange EF; Wehkamp J
PLoS One; 2013; 8(9):e73867. PubMed ID: 24040100
[TBL] [Abstract][Full Text] [Related]
8. Core-shell magnetic nanoparticles display synergistic antibacterial effects against
Niemirowicz K; Piktel E; Wilczewska AZ; Markiewicz KH; Durnaś B; Wątek M; Puszkarz I; Wróblewska M; Niklińska W; Savage PB; Bucki R
Int J Nanomedicine; 2016; 11():5443-5455. PubMed ID: 27799768
[TBL] [Abstract][Full Text] [Related]
9. Potential of ceragenin CSA-13 and its mixture with pluronic F-127 as treatment of topical bacterial infections.
Leszczyńska K; Namiot A; Cruz K; Byfield FJ; Won E; Mendez G; Sokołowski W; Savage PB; Bucki R; Janmey PA
J Appl Microbiol; 2011 Jan; 110(1):229-38. PubMed ID: 20961363
[TBL] [Abstract][Full Text] [Related]
10. Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo.
Durnaś B; Piktel E; Wątek M; Wollny T; Góźdź S; Smok-Kalwat J; Niemirowicz K; Savage PB; Bucki R
BMC Microbiol; 2017 Jul; 17(1):167. PubMed ID: 28747178
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activities of peptide Cbf-K
Jiang M; Ma L; Huang Y; Wu H; Dou J; Zhou C
Microb Pathog; 2020 Jan; 138():103847. PubMed ID: 31704464
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro antimicrobial susceptibility and synergistic activity of antimicrobial combinations against Helicobacter pylori isolates in Taiwan.
Cheng A; Sheng WH; Liou JM; Wang HP; Wu MS; Lin JT; Chang SC
J Microbiol Immunol Infect; 2015 Feb; 48(1):72-9. PubMed ID: 23036269
[TBL] [Abstract][Full Text] [Related]
13. Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells.
Niemirowicz K; Prokop I; Wilczewska AZ; Wnorowska U; Piktel E; Wątek M; Savage PB; Bucki R
Int J Nanomedicine; 2015; 10():3843-53. PubMed ID: 26082634
[TBL] [Abstract][Full Text] [Related]
14. Formulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13.
Niemirowicz K; Durnaś B; Tokajuk G; Piktel E; Michalak G; Gu X; Kułakowska A; Savage PB; Bucki R
Sci Rep; 2017 Jul; 7(1):4610. PubMed ID: 28676673
[TBL] [Abstract][Full Text] [Related]
15. Potent antibacterial activity of Y-754, a novel benzimidazole compound with selective action against Helicobacter pylori.
Iwao E; Yamamoto K; Yokoyama Y; Hirayama F; Haga K
J Infect Chemother; 2004 Apr; 10(2):90-6. PubMed ID: 15160301
[TBL] [Abstract][Full Text] [Related]
16. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivo.
Zhang XL; Jiang AM; Ma ZY; Li XB; Xiong YY; Dou JF; Wang JF
Molecules; 2015 Mar; 20(3):3972-85. PubMed ID: 25738539
[TBL] [Abstract][Full Text] [Related]
17. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat.
Pandya HB; Agravat HH; Patel JS; Sodagar NR
Indian J Med Microbiol; 2014; 32(4):408-13. PubMed ID: 25297026
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37.
McGee DJ; George AE; Trainor EA; Horton KE; Hildebrandt E; Testerman TL
Antimicrob Agents Chemother; 2011 Jun; 55(6):2897-904. PubMed ID: 21464244
[TBL] [Abstract][Full Text] [Related]
19. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.
Bucki R; Sostarecz AG; Byfield FJ; Savage PB; Janmey PA
J Antimicrob Chemother; 2007 Sep; 60(3):535-45. PubMed ID: 17584802
[TBL] [Abstract][Full Text] [Related]
20. Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis and Burkholderia pseudomallei.
Abdelbaqi S; Deslouches B; Steckbeck J; Montelaro R; Reed DS
J Med Microbiol; 2016 Feb; 65(2):188-194. PubMed ID: 26673248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
